Tumor cell recognition by the NK cell activating receptor NKG2D.
Evidence for increased tumor incidence in NKG2D-deficient mice has set NKG2D as the first innate immune receptor implicated in immunosurveillance of tumors. In this viewpoint article, we discuss recent genetic insight into NKG2D-mediated suppression of spontaneous tumor development in the context of NKG2D signaling properties. Moreover, we identify unresolved issues and consider how an understanding of NKG2D-receptor and -ligand biology can facilitate successful therapeutic intervention of human cancer.
Bryceson
Yenan T
YT
Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Ljunggren
Hans-Gustaf
HG
D000818:Animals; D058851:GPI-Linked Proteins; D006801:Humans; D007157:Immunologic Surveillance / Q000276:immunology; D036341:Intercellular Signaling Peptides and Proteins / Q000502:physiology; D055655:NK Cell Lectin-Like Receptor Subfamily K / Q000502:physiology*; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy; D015398:Signal Transduction; D019139:Tumor Escape / Q000276:immunology
D058851:GPI-Linked Proteins; D036341:Intercellular Signaling Peptides and Proteins; D055655:NK Cell Lectin-Like Receptor Subfamily K; C423230:ULBP2 protein, human